918n

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion under the trade name Zavesca. It is used primarily to treat type I Gaucher disease (GD1).

View More On Wikipedia.org
Recent contents Top users
  • L
    1

    lanie_perez

    Newbie
    • Posts
      2
    • Likes
      0
    • Points
      0
  • Y
    1

    y222

    Junior Member
    • Posts
      46
    • Likes
      2
    • Points
      0
    • Back
    Top